View drug registration information details.


ItemsRegistration information
ID523
No523
Brand NameHALAVEN SOLUTION FOR INJECTION
IngredientsEACH VIAL (2 ML) CONTAINS: ERIBULIN MESYLATE 1 MG EQ.TO ERIBULIN 0.88 MG.
Dosage FormSOLUTION FOR INJECTION
Primary PackagingVIAL
StorageSTORE BELOW 30'C
Shelf Life2 YEARS
Pack SizeBOX OF 1 VIAL X 2ML
Dispensing CategoryPrescription only
ATC ClassificationL01XX41
Pharmaceutical ClassANTINEOPLASTICS
IndicationsTREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE PROGRESSED AFTER AT LEAST TWO CHEMOTHERAPEUTIC REGIMENS FOR ADVANCED DISEASE. PRIOR THERAPY SHOULD HAVE INCLUDED AN ANTHRACYCLINE AND A TAXANE UNLESS PATIENTS WERE NOT SUITAB
Contraindications- HYPERSENSITIVITY TO THE ACTIVE SUBSTANCE OR TO ANY OF THE EXCIPIENTS - BREAST FEEDING
Side EffectsTHE MOST COMMONLY REPORTED ADVERSE REACTIONS TO ERIBULIN ARE SHOWN IN THE TABLE BELOW.
Unit Price-
EDL No
Description5 ML CLEAR GLASS VIAL CONTAINING A CLEAR, COLOURLESS SOLUTION ESPECIALLY FREE FROM VISIBLE PARTICLES OF FOREIGN MATTER
Note
License OwnerDKSH LAOS COMPANY LIMITED
ManufacturerBSP PHARMACEUTICALS S.P.A
CountryITALY
Import Registration NoEU/1/11/678/001
Import Registration Date2011-03-17
ActivityCERTIFICATE RELEASED
Applied Date2023-08-21
FDD Registration No09 I 3897/13
FDD Registration Date2024-01-08
Expiry Date2027-01-07

Back to drug list